Trial Profile
A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Dec 2022
Price :
$35
*
At a glance
- Drugs BMS 813160 (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Nov 2022 Planned End Date changed from 28 Oct 2024 to 14 Oct 2024.
- 03 Mar 2022 Planned End Date changed from 31 Jan 2025 to 28 Oct 2024.
- 22 Jul 2021 Planned number of patients changed from 39 to 53.